Results 21 to 30 of about 21,002 (228)

PharmacoEconomics Chat with Zanfina Ademi - The PALY

, 2021
The above video represents the opinions of the authors on their recent PharmacoEconomics article.The video has not been peer reviewed and is not published in the journal.This video is a part of our monthly webinar series PharmacoEconomics Chat, which is ...
Adis journals (11553853)
core   +1 more source

Pharmacoeconomics

YAKUGAKU ZASSHI, 2003
AbstractFor Abstract see ChemInform Abstract in Full Text.
openaire   +4 more sources

PharmacoEconomics Chat with Gian Luca Di Tanna - Heart Failure

, 2021
The above video represents the opinions of the authors on their recent PharmacoEconomics articles.The video has not been peer reviewed and is not published in the journal.This video is a part of our monthly webinar series PharmacoEconomics Chat, which is
adis journal authors (4873402)
core   +1 more source

Knowledge and practices regarding pharmacoeconomics among resident doctors in a tertiary care teaching hospital [PDF]

, 2020
Background: With skyrocketing health care costs, even the essential care provided by the health care service providers need to be evaluated under the lens.
Viveka, S., Sudha, M. J., A. R., Reshma Raj   +2 more
core   +1 more source

Instant velocity and consistency of emitted cloud change by the different levels of canister filling with Metered Dose Inhalers (MDIs), but not with Soft Mist Inhalers (SMIs): a bench study

Multidisciplinary Respiratory Medicine, 2017
Background Inhalation is the preferred route for respiratory drug delivery, but several factors contribute to the variability of the respirable dose fraction. Instant velocity and the dynamic characteristics of the droplet cloud represent crucial factors.
Roberto W. Dal Negro, Pietro Longo, Orestepaolo Villanis Ziani, Luca Bonadiman, Paola Turco   +4 more
doaj   +1 more source

Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model

Frontiers in Public Health, 2023
BackgroundA total of 11 treatment sequences for advanced wild-type squamous non-small cell lung cancer are recommended by Chinese Society of Clinical Oncology Guidelines, consisting of seven first-line and three second-line treatments.
Mingye Zhao, Mingye Zhao, Taihang Shao, Taihang Shao, Zhuoyuan Chi, Zhuoyuan Chi, Wenxi Tang, Wenxi Tang   +7 more
doaj   +1 more source

Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis

Arthritis Research & Therapy, 2017
Background Biologic disease-modifying antirheumatic drugs (DMARDs) are increasingly used for rheumatoid arthritis (RA) treatment. However, little is known based on contemporary data about the factors associated with DMARDs and patterns of use of biologic
Yinzhu Jin, Rishi J. Desai, Jun Liu, Nam-Kyong Choi, Seoyoung C. Kim   +4 more
doaj   +1 more source

Economic evaluation of five first-line PD-(L)1 inhibitors for treating non-squamous non-small cell lung cancer in China: A cost-effectiveness analysis based on network meta-analysis

Frontiers in Pharmacology, 2023
Background and objective: Non-small cell lung cancer (NSCLC) is one of the most malignant cancer types that causes substantial economic burden in China.
Xi Chen, Xi Chen, Mingye Zhao, Mingye Zhao, Lei Tian, Lei Tian   +5 more
doaj   +1 more source

Adapting Pharmacoeconomics to Shape Efficient Health Systems en Route to UHC – Lessons from Two Continents

Frontiers in Pharmacology, 2017
Background: Pharmacoeconomics is receiving increasing attention globally as a set of tools ensuring efficient use of resources in health systems, albeit with different applications depending on the contextual, cultural and development stages of each ...
Jacqui Miot, Michael Thiede
doaj   +1 more source

Economics, Pharmaceuticals, and Pharmacoeconomics

, 1998
Pharmacoeconomics, as the compound name suggests, is the application of principles of economic enquiry to pharmaceuticals. Although the label "pharmacoeconomics" has been used only for the last ten years or so, already there are a journal of the same ...
Johannesson, Magnus,, O'Brien, Bernie J.,   +1 more
core   +1 more source